These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31120856)

  • 21. Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden.
    Jonsson H; Holmström B; Duffy SW; Stattin P
    Int J Cancer; 2011 Oct; 129(8):1881-8. PubMed ID: 21154740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
    Pron G
    Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Navigating Prostate Cancer Screening in the Real World of Primary Care: The Mirage and the Quicksand.
    Mathew P; Hachem H; Han P
    JAMA Oncol; 2018 Apr; 4(4):453-454. PubMed ID: 29470576
    [No Abstract]   [Full Text] [Related]  

  • 24. Unravelling the prostate-specific antigen controversy: a West of Scotland perspective.
    Zafar N; Miller S; Leburn V; Qureshi KN; Rajan P
    Scott Med J; 2014 May; 59(2):126-9. PubMed ID: 24682103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer surveillance using registry data: Results and recommendations for the Lithuanian national prostate cancer early detection programme.
    Gondos A; Krilaviciute A; Smailyte G; Ulys A; Brenner H
    Eur J Cancer; 2015 Aug; 51(12):1630-7. PubMed ID: 26044924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications.
    Gershman B; Van Houten HK; Herrin J; Moreira DM; Kim SP; Shah ND; Karnes RJ
    Eur Urol; 2017 Jan; 71(1):55-65. PubMed ID: 26995328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.
    Carter HB
    BJU Int; 2013 Sep; 112(5):543-7. PubMed ID: 23924423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term consequences of the USPSTF Grade D recommendation for prostate-specific antigen screening.
    Joshi SS; Filson CP
    Cancer; 2020 Feb; 126(4):694-696. PubMed ID: 31794066
    [No Abstract]   [Full Text] [Related]  

  • 29. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
    Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
    BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relevance of total PSA and free PSA prescriptions.
    Lamy PJ; Brouillet JP; Bermont L; Fouillet G; Loric S
    Ann Biol Clin (Paris); 2018 Dec; 76(6):659-663. PubMed ID: 30543191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Change in prostate cancer presentation coinciding with USPSTF screening recommendations at a community-based urology practice.
    Gaylis FD; Choi JE; Hamilton Z; Dato P; Cohen E; Calabrese R; Prime H; Rosenbaum A; Kader AK
    Urol Oncol; 2017 Nov; 35(11):663.e1-663.e7. PubMed ID: 28736250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PSA testing for men at average risk of prostate cancer.
    Armstrong BK; Barry MJ; Frydenberg M; Gardiner RA; Haines I; Carter SM
    Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mass screening of 12,027 elderly men for prostate carcinoma by measuring serum prostate specific antigen.
    Zhang HF; Wang HL; Xu N; Li SW; Ji GY; Li XM; Pan YZ; Zhang L; Zhao XJ; Gao HW
    Chin Med J (Engl); 2004 Jan; 117(1):67-70. PubMed ID: 14733776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baseline prostate-specific antigen testing at a young age.
    Loeb S; Carter HB; Catalona WJ; Moul JW; Schroder FH
    Eur Urol; 2012 Jan; 61(1):1-7. PubMed ID: 21862205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
    Tawfik A
    Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Focus on the screening for prostate cancer by PSA].
    Roumeguère T; Van Velthoven R
    Rev Med Brux; 2013 Sep; 34(4):311-9. PubMed ID: 24195246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in the outcome of prostate biopsies after preventive task force recommendation against prostate-specific antigen screening.
    Zakaria AS; Dragomir A; Brimo F; Kassouf W; Tanguay S; Aprikian A
    BMC Urol; 2018 Aug; 18(1):69. PubMed ID: 30126402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate Cancer Screening and the Associated Controversy.
    Tabayoyong W; Abouassaly R
    Surg Clin North Am; 2015 Oct; 95(5):1023-39. PubMed ID: 26315521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deliberative democracy and cancer screening consent: a randomised control trial of the effect of a community jury on men's knowledge about and intentions to participate in PSA screening.
    Thomas R; Glasziou P; Rychetnik L; Mackenzie G; Gardiner R; Doust J
    BMJ Open; 2014 Dec; 4(12):e005691. PubMed ID: 25539779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate-specific antigen screening, why have the guidelines changed?
    Sountoulides P; Moutzouris G
    Expert Rev Anticancer Ther; 2014 Nov; 14(11):1277-81. PubMed ID: 25306859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.